[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"the-recovery-phase-of-septic-shock\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:the-recovery-phase-of-septic-shock":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100573355","recombinant-human-brain-natriuretic-peptide-for-the-recovery-stage-of-septic-shock-100573355",false,"NCT06745206","Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock","Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock: An Interventional Pilot Study","rh-BNP-RSS","Inclusion criteria:\n\n1. Age \\>18 years.\n2. Septic shock in recovery phase with decreasing vasopressor requirements, which is defined as:\n\n   1. Fulfilling the Sepsis-3 definition of septic shock at initial stage.\n   2. Hemodynamic stability achieved after adequate initial resuscitation and individualized hemodynamic optimization.\n   3. Controlled infection source with 48-hour trend of improving temperature, white blood cell count, and procalcitonin.\n   4. 48-hour trend of decreasing vasopressor requirements and transition to negative fluid balance.\n   5. Adequate perfusion with warm extremities, and capillary refill time \\\u003C3 seconds.\n3. Ongoing pulse index continuous cardiac output (PiCCO) hemodynamic monitoring and sinus rhythm.\n4. Volume indicators above the lower limit of normal range, with global end-diastolic volume index (GEDI) \\>680 mL\u002Fm2 and central venous pressure (CVP) \\>8 mmHg.\n5. Signs of cardiac dysfunction: BNP\\>200\\[10\\] or NT-proBNP \\>900 pg\u002Fml\\[6\\] or reduced ejection fraction (LVEF) \\\u003C 50%.\n6. No bolus dose of diuretics had been administered in the previous 6 hours.\n7. Informed consent obtained from patient\u002Flegal representative.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation.\n2. Arrhythmia.\n3. Advanced renal dysfunction (Acute Kidney Injury \\[AKI\\] stage 3 or Chronic Kidney Disease \\[CKD\\] stage 3b or higher) based on Kidney Disease: Improving Global Outcomes (KDIGO) criteria.\n4. Inadequate ultrasound window preventing acquisition of diagnostic-quality images.\n5. Trauma or neurological diseases (including intracerebral hemorrhage and cerebral infarction).\n6. Pre-existing severe heart failure (New York Heart Association \\[NYHA\\] class III-IV) or acute myocardial infarction within the past 30 days.\n7. Concurrent enrollment in interventional trials that could confound study outcomes.\n\nCriteria for withdrawing from the study:\n\n1. Withdrawal of the informed consent.\n2. Severe hemodynamic deterioration necessitating the discontinuation of all vasodilatory medications.\n3. Treating clinician's decision.","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","As infection control improves and circulation stabilizes, treatment de-escalation of septic shock begins, accompanied by fluid redistribution from interstitial spaces to the vasculature, increasing cardiac volume load. Synthetic recombinant human BNP (rh-BNP) plays a role in inducing vasodilation, particularly in the venous system, alleviating cardiac congestion, and enhancing natriuresis and diuresis. Thus the investigators designed a single-center, prospective physiological study to evaluate the efficacy of standard rh-BNP infusion in reducing venous return and enhancing fluid removal, with a secondary objective of assessing the maintenance of perfusion pressure and tissue perfusion.",[27,28],"Sepsis-induced Cardiomyopathy","the Recovery Phase of Septic Shock","NOT_YET_RECRUITING","2025-07-23",{"date":32,"type":33},"2025-07-29","ACTUAL",{"date":35,"type":21},"2025-12",{"date":37,"type":21},"2026-09",{"name":39,"class":40},"Sichuan Provincial People's Hospital","OTHER"]